---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-271921"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T17:06:36.923608+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics Q3 net loss $7.1M; cash $72M; SNS-101 Phase 1 data positive

## Summary
- Net loss $7.1M in Q3 2023 vs $13.4M in Q3 2022; cash $72.0M as of Sept 30, 2023, down from $107.1M at Dec 31, 2022.
- R&D expenses $3.8M vs $9.2M YoY; G&A $3.9M vs $4.8M; cash runway expected into H2 2025.
- SNS-101 Phase 1 data at SITC: no cytokine release syndrome, no dose-limiting toxicities, dose-proportional pharmacokinetics.
- Enrollment ahead of schedule: 17 patients treated; monotherapy dose escalation at 15 mg/kg; combination arm cleared 3 mg/kg.
- Apped Stephanie Krebs as CBO; SNS-201 and SNS-102 lead candidates selected; milestones: combo data Q1 2024, monotherapy topline Q2 2024.

## SEC filing metadata
- accession: 0001193125-23-271921
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312523271921/0001193125-23-271921-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312523271921/d908748d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-271921
- JSON: https://secwatch.observer/filing/0001193125-23-271921.json
- Plain text: https://secwatch.observer/filing/0001193125-23-271921.txt

## Key facts
- Earnings Releases
  Sensei Biotherapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312523271921/0001193125-23-271921-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.